Skip to main content
Edition No. 102 · GlobalEst. 2026
S&P 5007,299.27-2.95%Dow Jones50,576.53-3.17%Nasdaq24,150.09-3.65%FTSE 10010,689.87-0.57%DAX26,045.37-1.15%Nikkei 22558,860.43-3.90%Hang Seng23,508.17-4.27%EUR/USD1.1012-1.41%GBP/USD1.3216-1.00%Gold3,851.40-0.87%Crude Oil85.60-3.54%Bitcoin63,611.07-6.80%S&P 5007,299.27-2.95%Dow Jones50,576.53-3.17%Nasdaq24,150.09-3.65%FTSE 10010,689.87-0.57%DAX26,045.37-1.15%Nikkei 22558,860.43-3.90%Hang Seng23,508.17-4.27%EUR/USD1.1012-1.41%GBP/USD1.3216-1.00%Gold3,851.40-0.87%Crude Oil85.60-3.54%Bitcoin63,611.07-6.80%

New HIV Dosing Regimen Approved for Newborns Following International Clinical Trial

Researchers establish safe and effective dolutegravir dosing for infants from birth to improve early treatment outcomes.

By Planet Earth News Medicine Desk· Published 2026-11-01· 2 min read
PENN Explainer

Hear this story explained in 90 seconds.

An international clinical trial has successfully identified a safe and effective dosing regimen for the drug dolutegravir in full-term newborns. This development recently informed the U.S. Food and Drug Administration's decision to approve the medication for the treatment of HIV-1 in infants starting from the first days of life. Previously, this second-generation integrase inhibitor was only authorized for use in children aged four weeks and older. The findings were published in the medical journal The Lancet HIV, marking a significant step forward in pediatric care. Newborns process medications differently than adults, and their ability to eliminate drugs changes rapidly during their first month of life. This study provides the necessary pharmacokinetic and safety data to guide proper dosing during this critical developmental period. The research was conducted through the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, known as IMPAACT. The study, titled IMPAACT 2023, was a Phase I clinical trial that took place across multiple research sites in South Africa, Thailand, and the United States. It was led by researchers at Boston Medical Center, with significant contributions from the University of California San Diego. By establishing a clear dosing schedule, the medical community can now expand access to this widely used antiretroviral medication for the youngest patients. This change ensures that infants exposed to HIV can receive treatment immediately after birth rather than waiting for several weeks. The approval reflects a broader effort to improve health outcomes for children born with HIV by utilizing established, effective therapies earlier in life. Future efforts will continue to monitor the long-term safety and efficacy of this dosing strategy in diverse populations. This advancement highlights the importance of conducting pediatric-specific clinical trials to ensure that life-saving drugs are safe for all age groups.

You've reached your free article limit

You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.

Already a subscriber? Sign in.

Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Neutrality note

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Medicine